

**CONFIDENTIAL**



**TheraGuide 5-FU™  
Analysis Result**

PHYSICIAN  
**John Doe MD**  
Myriad Genetics, Inc.  
320 Wakara Way  
Salt Lake City, UT 84108

SPECIMEN  
Specimen Type: **Blood**  
Draw Date: **Sep 1, 2007**  
Accession Date: **Sep 5, 2007**  
Report Date: **Sep 7, 2007**

PATIENT  
Name: **Doe, Jane**  
Date of Birth:  
Patient ID:  
Gender: **Female**  
Accession #: **00254459-BLD**  
Requisition #: **00254459**

**Test Results and Interpretation**

**INDETERMINATE RISK**

<u>Genes Analyzed</u>	<u>Results</u>	<u>Interpretation</u>
DPYD	S534N (1601G>A)	Uncertain Significance
TYMS	2R/3R	Low Risk

DPYD : S534N (1601G>A) : Dihydropyrimidine dehydrogenase (DPYD) gene analysis identified a heterozygous substitution of asparagine for serine at amino acid position 534 of the DPYD protein. Variants of this type may or may not affect the function of the protein encoded by the gene in which it is found. Therefore, the contribution of the DPYD variant to the relative risk of 5-FU toxicity cannot be established solely from this analysis. There may be other rare abnormalities at the DPYD locus that are not detected by this analysis.

TYMS : 2R/3R : Thymidylate synthetase (TYMS) gene analysis identified the 2R/3R genotype. In previous studies patients with this genotype have no increased risk of 5-FU toxicity compared to the general population [2-4].

Increased susceptibility to 5-FU toxicity may be associated with other risk factors not detected by this analysis. Approximately one third of patients taking 5-FU have evidence of some toxic side effects that are clinically apparent.

**Analysis Description :** This test is designed to identify mutations in 23 coding exons and approximately 690 adjacent intronic base pairs of DPYD and also to identify the number of 28 base pair repeats with the 5'UTR region of the TYMS gene.

**Additional Information :** General information about TheraGuide 5-FU™ can be found at [myriadtests.com](http://myriadtests.com). If you have any questions regarding this report, please do not hesitate to contact Medical Services at 1-800-469-7423.

**References:**

1. Mol Cancer Ther. 2006; 5(11):2895-2904
2. Clin Cancer Res. 2004; 10(17):5880-5888
3. Clin Cancer Res. 2006; 12(13):3928-3934
4. Pharmacogenomics. 2001; J1:65-70

**Authorized Signature:**

Richard J. Wenstrup, MD Diplomate ABMG Chief Medical Officer	Karla Bowles, Ph.D. Diplomate ABMG Associate Laboratory Director	M. Junaid Shabbeer, Ph.D. Diplomate ABMG Assistant Laboratory Director
Benjamin B. Roa, Ph.D. Diplomate ABMG Laboratory Director	W. Christine Spence, Ph.D. Diplomate ABMG Associate Laboratory Director	John P Tazelaar, MD Diplomate ABP Associate Laboratory Director

The accompanying Technical Specifications summary describes the analysis, method, performance characteristics, nomenclature, and interpretive criteria of this test. This test may be considered investigational in some states. This test was developed and its performance characteristics determined by Myriad Genetics Laboratories. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.